Factors Affecting the Pharmacology of Antibody-Drug Conjugates
Andrew T Lucas1,2,3, Lauren S L Price4, Allison N Schorzman5
1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. andrew_lucas@unc.edu.
Abstract:
Major advances in therapeutic proteins, including antibody-drug conjugates (ADCs), have created revolutionary drug delivery systems in cancer over the past decade. While these immunoconjugate agents provide several advantages compared to their small-molecule counterparts, their clinical use is still in its infancy. The considerations in their development and clinical use are complex, and consist of multiple components and variables that can affect the pharmacologic characteristics. It is critical to understand the mechanisms employed by ADCs in navigating biological barriers and how these factors affect their biodistribution, delivery to tumors, efficacy, and toxicity. Thus, future studies are warranted to better understand the complex pharmacology and interaction between ADC carriers and biological systems, such as the mononuclear phagocyte system (MPS) and tumor microenvironment. This review provides an overview of factors that affect the pharmacologic profiles of ADC therapies that are currently in clinical use and development.
Insights
Antibody-drug conjugates (ADCs) are revolutionary cancer therapies. Understanding their complex pharmacology and interactions with biological systems is crucial for optimizing efficacy and minimizing toxicity.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Therapeutic proteins, particularly antibody-drug conjugates (ADCs), represent significant advancements in cancer treatment.
- Despite their advantages over small-molecule drugs, the clinical application of ADCs is still emerging.
- The development and clinical use of ADCs involve intricate factors influencing their pharmacological properties.
Purpose of the Study:
- To provide an overview of factors impacting the pharmacologic profiles of ADC therapies.
- To highlight the critical need for understanding ADC mechanisms in navigating biological barriers.
- To emphasize the importance of studying ADC interactions with biological systems like the mononuclear phagocyte system (MPS) and tumor microenvironment.
Main Methods:
- Review of current clinical and developmental factors affecting ADC pharmacologic profiles.
- Analysis of mechanisms by which ADCs interact with biological barriers.
- Examination of the influence of biological systems on ADC biodistribution, tumor delivery, efficacy, and toxicity.
Main Results:
- ADCs offer novel drug delivery systems for cancer therapy.
- Multiple components and variables significantly affect ADC pharmacologic characteristics.
- Understanding ADC navigation of biological barriers is key to their effective use.
Conclusions:
- Further research is essential to elucidate the complex pharmacology of ADCs.
- Investigating the interplay between ADC carriers and biological systems is critical for future therapeutic development.
- Optimizing ADC therapies requires a comprehensive understanding of their biodistribution, tumor targeting, and systemic interactions.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
Related Concept Videos
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:19Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
01:21Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...